23andMe Holding Co. (ME)
|Net Income (ttm)||-225.63M|
|Day's Range||8.46 - 9.30|
|52-Week Range||7.01 - 18.16|
|Price Target||13.00 (+45.1%)|
|Est. Earnings Date||Nov 12, 2021|
23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a ... [Read more...]
In 2020, 23andMe's revenue was $243.92 million, a decrease of -20.15% compared to the previous year's $305.46 million. Losses were -$183.62 million, -26.81% less than in 2019.Financial Statements
‘Absolutely' a future where everyone's DNA sequenced at birth: 23andMe CEO
23andMe Co-Founder & CEO Anne Wojcicki joins 'Influencers with Andy Serwer' to discuss the future of personal genomics. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: h...
Despite losing millions right now, this company could have massive long-term growth potential.
The billionaire's blank-check company proved to be a bust, but these seven other SPACs still have a shot at becoming long-term winners. The post 7 SPACs to Buy That Are Better Than Bill Ackman's Pershin...
Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions.
Many recent SPAC IPOs have been hammered, and these two could be worth a closer look.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
23andMe (ME) stock is rising higher on Tuesday after Credit Suisse weighed in on the personal genomics and biotechnology company. The post ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today a...
It's no great secret why Credit Suisse likes 23andMe.
23andMe Holding Co. (NASDAQ:ME) shares are trading higher by 6.6% at $7.77 Tuesday morning after Credit Suisse initiated coverage on the stock with an Outperform rating and announced a $13 price target....
First quarter revenue up 23% over prior year Strong cash balance of $770 million Continuing to advance therapeutics portfolio to drive future revenue growth
The SPAC boom has died down, but IPOs have not.
Yes, but it'll take a while to grow with gusto.
This innovative consumer genetic testing company is more than meets the eye.
Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe's Board as the Company Sets to Accelerate Personalized Healthcare Based on Human Genetics Dr. Valerie Montgomery Rice and Peter Taylor Join 23an...
23andMe CEO on public debut, future of genetic testing
This segment originally aired on June 17, 2021. DNA testing company 23andMe started trading on Thursday, under the ticker ‘ME'.
23andMe (ME) stock is on the move Friday after the genetics company made its public debut on the Nasdaq Exchange yesterday. The post ME Stock: 14 Things for Investors to Know About 23andMe Following Its...
23andMe CEO on Trading Debut, GSK Deal, Branson SPAC
Jun.17 -- 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company's NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a mer...
DNA Testing Company 23andMe Makes Nasdaq Debut
Consumer genetic testing company 23andMe has made its Nasdaq debut at about $11 a share. CEO Anne Wojcicki joined Cheddar to talk about taking the company public through a SPAC merger.
The company is the latest to go public via a SPAC deal. 23andMe, the direct-to-consumer genetic testing company headquartered in Sunnyvale, California, popped on its stock market debut Thursday.
Congratulations, 23andMe. You're a public stock now!
Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17 Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17